SEC Form 4 · accession 0001209191-15-061523

Horizon Pharma plc · HZNP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP and Chief Medical Officer

Period of report

Jul 15, 2015

Accepted (ET)

Jul 17, 2015 · 4:36 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001492426

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares^F1	Jul 15, 2015	M	24,437	$2.40	A	137,319	D
Ordinary Shares^F3	Jul 15, 2015	S	24,437	$35.55	D	112,882	D
Ordinary Shares	Jul 15, 2015	M	2,450	$4.96	A	115,332	D
Ordinary Shares^F3	Jul 15, 2015	S	2,450	$35.55	D	112,882	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$2.40	Jul 15, 2015	M	24,437	D	—	Jan 1, 2023	Ordinary Shares	24,437	26,563	D
Stock Option (Right to Buy)^F4	$4.96	Jul 15, 2015	M	2,450	D	—	Dec 7, 2021	Ordinary Shares	2,450	51,171	D

F1Includes 10,549 ordinary shares of the Issuer acquired by the reporting person on June 1, 2015 pursuant to an employee stock purchase program.
F2The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on May 13, 2015.
F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.09 to $35.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4The stock option vests in 48 equal monthly installments following the date of grant.